Department of Molecular Neurobiology

dr hab. Maciej Figiel

Dr. habil. Maciej Figiel

Head of Department


mfigiel@ibch.poznan.pl
ext. 1150

Researchers:

Dr. Magdalena Surdyka
adiunkt

Urszula Kozłowska
adiunkt

Research Projects

Research area
  • New mechanisms of neurodegeneration in poliq model diseases.
  • Characterization of SCA3/MJD KI91 knock-in mouse model.
  • Identification of changes in the level of mRNA and proteins, and modifications (phosphoproteins, ubiquitinated proteins) in different stages of diseases development in the KI91 model.
  • Behavioral characterization of the KI91 mice.
  • Identyfication of new molecular therapeutic targets in poliQ diseases.
  • Therapy of polyQ diseases.
  • Generation of iPSC models of neurodegenerativ diseases.
  • Neurodegenerative disease = neurodevelopmental disease. The study of the pathogenesis
  • of neurodegenerativ disease on the development axis: stem cells - neuronal stem cells - mature neuronal cells.
  • Identyfication and validation of RNA species with altered expression level in human Huntington disease iPSC.
Keywords
  • Neurodegenerative disorders,
  • neurodevelopmental disorders,
  • mouse models,
  • induced pluripotent stem cells,
  • iPSC, SCA3, MJD,
  • #spinocerebellar ataxia type 3,
  • Machado Joseph Disease,
  • Huntington disease

Research activity

  • Allele selective, CAG-targeted RNAi-based strategy to lower mutant polyQ proteins in polyglutamine ataxias; National Ataxia Foundation; Minneapolis, MN, USA; 688790; Pioneer SCA3/MJD Translational Research Award; Maciej Figiel and Yvon Trottier
  • Discovering disorders of brain development in Huntington disease as a consequence of possible total huntingtin deficiency in HD, using juvenile HD iPSC and fused brain organoids; National Science Center, Grant number: 2018/31/B/NZ3/03621
  • Allele-specific lowering of mutant polyQ proteins as treatment for Huntington disease, spinocerebellar ataxia type 3 and spinocerebellar ataxia type 7; National Centre for Research and Development; Grant number: ERA-NET-E-RARE-3/III/TreatPolyQ/08/2018
  • Gene Therapy for Cerebellar Ataxias: restoring cholesterol metabolism by targeting brain cholesterol 24 hydroxylase (CYP46A1); National Centre for Research and Development; Grant number: ERA-NET-E-RARE-3/III/SCA-CYP/09/2018
  • Defining new mechanisms of neurodegeneration using the first model of a knock-in SCA3 / MJD; National Science Center (Krakow); Grant number: 2013/10/E/NZ4/00621
Skip to content